Moderna Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thank you for joining us for Day 2 of the Goldman Sachs Healthcare Conference. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to be joined by Moderna. With us, we have Stephane Bancel, CEO of the company.
Questions & Answers
With that, Stephane, thank you so much for joining us. And to start here, a question on your modalities. You have established 2 modalities or 2 verticals out of the 6 right now, prophylactic vaccines, systemic secreted and cell surface therapeutics as core. And can you remind us what this means and speak to the biological and technology risks that remain in all your exploratory modalities, and the steps needed to derisk these verticals on the forward.
Great. Good morning, Salveen, and thank you for the invitation. So maybe let me
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |